Drugs interactions for Twyneo®

  • 201 Major drug interactions (including ingredients like Abametapir, Aceclofenac, Acetylsalicylic acid)
  • 175 Moderate drug interactions (including ingredients like Abatacept, Adalimumab, Aminolevulinic acid)
  • 193 Minor drug interactions (including ingredients like Acalabrutinib, Acebutolol, Aliskiren)
569 interactions for Twyneo®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Twyneo®.
Abametapir
The serum concentration of Tretinoin can be increased when it is combined with Abametapir.
Aceclofenac
The risk or severity of elevated intracranial pressure can be increased when Aceclofenac is combined with Tretinoin.
Acetylsalicylic acid
The risk or severity of elevated intracranial pressure can be increased when Acetylsalicylic acid is combined with Tretinoin.
Albuterol
The risk or severity of elevated intracranial pressure can be increased when Salbutamol is combined with Tretinoin.
Alfentanil
The risk or severity of elevated intracranial pressure can be increased when Alfentanil is combined with Tretinoin.
Almotriptan
The risk or severity of elevated intracranial pressure can be increased when Almotriptan is combined with Tretinoin.
Alpha-1-proteinase inhibitor
The risk or severity of Thrombosis can be increased when Alpha-1-proteinase inhibitor is combined with Tretinoin.
Aminocaproic acid
The risk or severity of Thrombosis can be increased when Aminocaproic acid is combined with Tretinoin.
Amitriptyline
The risk or severity of elevated intracranial pressure can be increased when Amitriptyline is combined with Tretinoin.
Amoxapine
The risk or severity of elevated intracranial pressure can be increased when Amoxapine is combined with Tretinoin.
Amphetamine
The risk or severity of elevated intracranial pressure can be increased when Amphetamine is combined with Tretinoin.
Antipyrine
The risk or severity of elevated intracranial pressure can be increased when Antipyrine is combined with Tretinoin.
Arformoterol
The risk or severity of elevated intracranial pressure can be increased when Arformoterol is combined with Tretinoin.
Aripiprazole
The risk or severity of elevated intracranial pressure can be increased when Aripiprazole is combined with Tretinoin.
Aripiprazole lauroxil
The risk or severity of elevated intracranial pressure can be increased when Aripiprazole lauroxil is combined with Tretinoin.
Asenapine
The risk or severity of elevated intracranial pressure can be increased when Asenapine is combined with Tretinoin.
Atomoxetine
The risk or severity of elevated intracranial pressure can be increased when Atomoxetine is combined with Tretinoin.
Atropine
The risk or severity of elevated intracranial pressure can be increased when Atropine is combined with Tretinoin.
Axitinib
The metabolism of Axitinib can be decreased when combined with Tretinoin.
Balsalazide
The risk or severity of elevated intracranial pressure can be increased when Balsalazide is combined with Tretinoin.
Benzphetamine
The risk or severity of elevated intracranial pressure can be increased when Benzphetamine is combined with Tretinoin.
Brexpiprazole
The risk or severity of elevated intracranial pressure can be increased when Brexpiprazole is combined with Tretinoin.
Bromocriptine
The risk or severity of elevated intracranial pressure can be increased when Bromocriptine is combined with Tretinoin.
Buspirone
The risk or severity of elevated intracranial pressure can be increased when Buspirone is combined with Tretinoin.
Cabazitaxel
The metabolism of Cabazitaxel can be decreased when combined with Tretinoin.
Cabergoline
The risk or severity of elevated intracranial pressure can be increased when Cabergoline is combined with Tretinoin.
Cannabidiol
The risk or severity of elevated intracranial pressure can be increased when Cannabidiol is combined with Tretinoin.
Cariprazine
The risk or severity of elevated intracranial pressure can be increased when Cariprazine is combined with Tretinoin.
Celecoxib
The risk or severity of elevated intracranial pressure can be increased when Celecoxib is combined with Tretinoin.
Chlorpromazine
The risk or severity of elevated intracranial pressure can be increased when Chlorpromazine is combined with Tretinoin.
Clomipramine
The risk or severity of elevated intracranial pressure can be increased when Clomipramine is combined with Tretinoin.
Clonidine
The risk or severity of elevated intracranial pressure can be increased when Clonidine is combined with Tretinoin.
Clozapine
The risk or severity of elevated intracranial pressure can be increased when Clozapine is combined with Tretinoin.
Copanlisib
The metabolism of Copanlisib can be decreased when combined with Tretinoin.
Crizotinib
The metabolism of Crizotinib can be decreased when combined with Tretinoin.
Cyclophosphamide
The metabolism of Cyclophosphamide can be decreased when combined with Tretinoin.
Cyclosporine
The risk or severity of elevated intracranial pressure can be increased when Cyclosporine is combined with Tretinoin.
Dapiprazole
The risk or severity of elevated intracranial pressure can be increased when Dapiprazole is combined with Tretinoin.
Demeclocycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Demeclocycline.
Desflurane
The risk or severity of elevated intracranial pressure can be increased when Desflurane is combined with Tretinoin.
Desipramine
The risk or severity of elevated intracranial pressure can be increased when Desipramine is combined with Tretinoin.
Desmopressin
The risk or severity of elevated intracranial pressure can be increased when Desmopressin is combined with Tretinoin.
Dexmedetomidine
The risk or severity of elevated intracranial pressure can be increased when Dexmedetomidine is combined with Tretinoin.
Dexmethylphenidate
The risk or severity of elevated intracranial pressure can be increased when Dexmethylphenidate is combined with Tretinoin.
Dextroamphetamine
The risk or severity of elevated intracranial pressure can be increased when Dextroamphetamine is combined with Tretinoin.
Diclofenac
The risk or severity of elevated intracranial pressure can be increased when Diclofenac is combined with Tretinoin.
Diethylpropion
The risk or severity of elevated intracranial pressure can be increased when Diethylpropion is combined with Tretinoin.
Diflunisal
The risk or severity of elevated intracranial pressure can be increased when Diflunisal is combined with Tretinoin.
Dihydroergocornine
The risk or severity of elevated intracranial pressure can be increased when Dihydroergocornine is combined with Tretinoin.
Dihydroergocristine
The risk or severity of elevated intracranial pressure can be increased when Dihydroergocristine is combined with Tretinoin.
Dihydroergotamine
The risk or severity of elevated intracranial pressure can be increased when Dihydroergotamine is combined with Tretinoin.
Diltiazem
The metabolism of Tretinoin can be decreased when combined with Diltiazem.
DL-Methylephedrine
The risk or severity of elevated intracranial pressure can be increased when DL-Methylephedrine is combined with Tretinoin.
Dobutamine
The risk or severity of elevated intracranial pressure can be increased when Dobutamine is combined with Tretinoin.
Docetaxel
The metabolism of Docetaxel can be decreased when combined with Tretinoin.
Dopamine
The risk or severity of elevated intracranial pressure can be increased when Dopamine is combined with Tretinoin.
Doxapram
The risk or severity of elevated intracranial pressure can be increased when Doxapram is combined with Tretinoin.
Doxepin
The risk or severity of elevated intracranial pressure can be increased when Doxepin is combined with Tretinoin.
Doxycycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Doxycycline.
Dronedarone
The risk or severity of elevated intracranial pressure can be increased when Dronedarone is combined with Tretinoin.
Droperidol
The risk or severity of elevated intracranial pressure can be increased when Droperidol is combined with Tretinoin.
Droxidopa
The risk or severity of elevated intracranial pressure can be increased when Droxidopa is combined with Tretinoin.
Dutasteride
The risk or severity of elevated intracranial pressure can be increased when Dutasteride is combined with Tretinoin.
Eletriptan
The risk or severity of elevated intracranial pressure can be increased when Eletriptan is combined with Tretinoin.
Ephedrine
The risk or severity of elevated intracranial pressure can be increased when Ephedrine is combined with Tretinoin.
Epinephrine
The risk or severity of elevated intracranial pressure can be increased when Epinephrine is combined with Tretinoin.
Eravacycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Eravacycline.
Ergotamine
The risk or severity of elevated intracranial pressure can be increased when Ergotamine is combined with Tretinoin.
Erlotinib
The metabolism of Erlotinib can be decreased when combined with Tretinoin.
Ethenzamide
The risk or severity of elevated intracranial pressure can be increased when Ethenzamide is combined with Tretinoin.
Etodolac
The risk or severity of elevated intracranial pressure can be increased when Etodolac is combined with Tretinoin.
Etomidate
The risk or severity of elevated intracranial pressure can be increased when Etomidate is combined with Tretinoin.
Etoposide
The metabolism of Etoposide can be decreased when combined with Tretinoin.
Fenoprofen
The risk or severity of elevated intracranial pressure can be increased when Fenoprofen is combined with Tretinoin.
Fentanyl
The risk or severity of elevated intracranial pressure can be increased when Fentanyl is combined with Tretinoin.
Finasteride
The risk or severity of elevated intracranial pressure can be increased when Finasteride is combined with Tretinoin.
Flibanserin
The risk or severity of elevated intracranial pressure can be increased when Flibanserin is combined with Tretinoin.
Flurbiprofen
The risk or severity of elevated intracranial pressure can be increased when Flurbiprofen is combined with Tretinoin.
Formoterol
The risk or severity of elevated intracranial pressure can be increased when Formoterol is combined with Tretinoin.
Frovatriptan
The risk or severity of elevated intracranial pressure can be increased when Frovatriptan is combined with Tretinoin.
Guanfacine
The risk or severity of elevated intracranial pressure can be increased when Guanfacine is combined with Tretinoin.
Hydrogen peroxide
The risk or severity of Thrombosis can be increased when Hydrogen peroxide is combined with Tretinoin.
Ibuprofen
The risk or severity of elevated intracranial pressure can be increased when Ibuprofen is combined with Tretinoin.
Icosapent
The risk or severity of elevated intracranial pressure can be increased when Icosapent is combined with Tretinoin.
Ifosfamide
The metabolism of Ifosfamide can be decreased when combined with Tretinoin.
Iloperidone
The risk or severity of elevated intracranial pressure can be increased when Iloperidone is combined with Tretinoin.
Imipramine
The risk or severity of elevated intracranial pressure can be increased when Imipramine is combined with Tretinoin.
Indomethacin
The risk or severity of elevated intracranial pressure can be increased when Indomethacin is combined with Tretinoin.
Isocarboxazid
The risk or severity of elevated intracranial pressure can be increased when Isocarboxazid is combined with Tretinoin.
Isoflurane
The risk or severity of elevated intracranial pressure can be increased when Isoflurane is combined with Tretinoin.
Isoprenaline
The risk or severity of elevated intracranial pressure can be increased when Isoprenaline is combined with Tretinoin.
Isoxsuprine
The risk or severity of elevated intracranial pressure can be increased when Isoxsuprine is combined with Tretinoin.
Ketoprofen
The risk or severity of elevated intracranial pressure can be increased when Ketoprofen is combined with Tretinoin.
Ketorolac
The risk or severity of elevated intracranial pressure can be increased when Ketorolac is combined with Tretinoin.
Levonordefrin
The risk or severity of elevated intracranial pressure can be increased when Levonordefrin is combined with Tretinoin.
Levosalbutamol
The risk or severity of elevated intracranial pressure can be increased when Levosalbutamol is combined with Tretinoin.
Linezolid
The risk or severity of elevated intracranial pressure can be increased when Linezolid is combined with Tretinoin.
Lisdexamfetamine
The risk or severity of elevated intracranial pressure can be increased when Lisdexamfetamine is combined with Tretinoin.
Lofexidine
The risk or severity of elevated intracranial pressure can be increased when Lofexidine is combined with Tretinoin.
Lurasidone
The risk or severity of elevated intracranial pressure can be increased when Lurasidone is combined with Tretinoin.
Magnesium salicylate
The risk or severity of elevated intracranial pressure can be increased when Magnesium salicylate is combined with Tretinoin.
Meclofenamic acid
The risk or severity of elevated intracranial pressure can be increased when Meclofenamic acid is combined with Tretinoin.
Mefenamic acid
The risk or severity of elevated intracranial pressure can be increased when Mefenamic acid is combined with Tretinoin.
Meloxicam
The risk or severity of elevated intracranial pressure can be increased when Meloxicam is combined with Tretinoin.
Mesalazine
The risk or severity of elevated intracranial pressure can be increased when Mesalazine is combined with Tretinoin.
Metamfetamine
The risk or severity of elevated intracranial pressure can be increased when Metamfetamine is combined with Tretinoin.
Metaraminol
The risk or severity of elevated intracranial pressure can be increased when Metaraminol is combined with Tretinoin.
Methylene blue
The risk or severity of elevated intracranial pressure can be increased when Methylene blue is combined with Tretinoin.
Methylergometrine
The risk or severity of elevated intracranial pressure can be increased when Methylergometrine is combined with Tretinoin.
Methylphenidate
The risk or severity of elevated intracranial pressure can be increased when Methylphenidate is combined with Tretinoin.
Midodrine
The risk or severity of elevated intracranial pressure can be increased when Midodrine is combined with Tretinoin.
Minocycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Minocycline.
Mirabegron
The risk or severity of elevated intracranial pressure can be increased when Mirabegron is combined with Tretinoin.
Mirtazapine
The risk or severity of elevated intracranial pressure can be increased when Mirtazapine is combined with Tretinoin.
Nabumetone
The risk or severity of elevated intracranial pressure can be increased when Nabumetone is combined with Tretinoin.
Naphazoline
The risk or severity of elevated intracranial pressure can be increased when Naphazoline is combined with Tretinoin.
Naproxen
The risk or severity of elevated intracranial pressure can be increased when Naproxen is combined with Tretinoin.
Naratriptan
The risk or severity of elevated intracranial pressure can be increased when Naratriptan is combined with Tretinoin.
Naxitamab
The risk or severity of elevated intracranial pressure can be increased when Naxitamab is combined with Tretinoin.
Nefazodone
The risk or severity of elevated intracranial pressure can be increased when Nefazodone is combined with Tretinoin.
Nitrous oxide
The risk or severity of elevated intracranial pressure can be increased when Nitrous oxide is combined with Tretinoin.
Norepinephrine
The risk or severity of elevated intracranial pressure can be increased when Norepinephrine is combined with Tretinoin.
Nortriptyline
The risk or severity of elevated intracranial pressure can be increased when Nortriptyline is combined with Tretinoin.
Olaparib
The metabolism of Olaparib can be decreased when combined with Tretinoin.
Olodaterol
The risk or severity of elevated intracranial pressure can be increased when Olodaterol is combined with Tretinoin.
Omadacycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Omadacycline.
Orciprenaline
The risk or severity of elevated intracranial pressure can be increased when Orciprenaline is combined with Tretinoin.
Oxaprozin
The risk or severity of elevated intracranial pressure can be increased when Oxaprozin is combined with Tretinoin.
Oxymetazoline
The risk or severity of elevated intracranial pressure can be increased when Oxymetazoline is combined with Tretinoin.
Oxytetracycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Oxytetracycline.
Paclitaxel
The metabolism of Paclitaxel can be decreased when combined with Tretinoin.
Paliperidone
The risk or severity of elevated intracranial pressure can be increased when Paliperidone is combined with Tretinoin.
Palovarotene
The risk or severity of adverse effects can be increased when Tretinoin is combined with Palovarotene.
Parecoxib
The risk or severity of elevated intracranial pressure can be increased when Parecoxib is combined with Tretinoin.
Pergolide
The risk or severity of elevated intracranial pressure can be increased when Pergolide is combined with Tretinoin.
Phendimetrazine
The risk or severity of elevated intracranial pressure can be increased when Phendimetrazine is combined with Tretinoin.
Phenelzine
The risk or severity of elevated intracranial pressure can be increased when Phenelzine is combined with Tretinoin.
Phenoxybenzamine
The risk or severity of elevated intracranial pressure can be increased when Phenoxybenzamine is combined with Tretinoin.
Phentermine
The risk or severity of elevated intracranial pressure can be increased when Phentermine is combined with Tretinoin.
Phentolamine
The risk or severity of elevated intracranial pressure can be increased when Phentolamine is combined with Tretinoin.
Phenylephrine
The risk or severity of elevated intracranial pressure can be increased when Phenylephrine is combined with Tretinoin.
Pimozide
The metabolism of Pimozide can be decreased when combined with Tretinoin.
Piroxicam
The risk or severity of elevated intracranial pressure can be increased when Piroxicam is combined with Tretinoin.
Ponatinib
The metabolism of Ponatinib can be decreased when combined with Tretinoin.
Propafenone
The risk or severity of elevated intracranial pressure can be increased when Propafenone is combined with Tretinoin.
Propofol
The risk or severity of elevated intracranial pressure can be increased when Propofol is combined with Tretinoin.
Propyphenazone
The risk or severity of elevated intracranial pressure can be increased when Propyphenazone is combined with Tretinoin.
Protriptyline
The risk or severity of elevated intracranial pressure can be increased when Protriptyline is combined with Tretinoin.
Pseudoephedrine
The risk or severity of elevated intracranial pressure can be increased when Pseudoephedrine is combined with Tretinoin.
Quetiapine
The risk or severity of elevated intracranial pressure can be increased when Quetiapine is combined with Tretinoin.
Quinidine
The risk or severity of elevated intracranial pressure can be increased when Quinidine is combined with Tretinoin.
Racepinephrine
The risk or severity of elevated intracranial pressure can be increased when Racepinephrine is combined with Tretinoin.
Rasagiline
The risk or severity of elevated intracranial pressure can be increased when Rasagiline is combined with Tretinoin.
Remifentanil
The risk or severity of elevated intracranial pressure can be increased when Remifentanil is combined with Tretinoin.
Risperidone
The risk or severity of elevated intracranial pressure can be increased when Risperidone is combined with Tretinoin.
Rizatriptan
The risk or severity of elevated intracranial pressure can be increased when Rizatriptan is combined with Tretinoin.
Rotigotine
The risk or severity of elevated intracranial pressure can be increased when Rotigotine is combined with Tretinoin.
Safinamide
The risk or severity of elevated intracranial pressure can be increased when Safinamide is combined with Tretinoin.
Salicylamide
The risk or severity of elevated intracranial pressure can be increased when Salicylamide is combined with Tretinoin.
Salicylic acid
The risk or severity of elevated intracranial pressure can be increased when Salicylic acid is combined with Tretinoin.
Salmeterol
The risk or severity of elevated intracranial pressure can be increased when Salmeterol is combined with Tretinoin.
Salsalate
The risk or severity of elevated intracranial pressure can be increased when Salsalate is combined with Tretinoin.
Sarecycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Sarecycline.
Selegiline
The risk or severity of elevated intracranial pressure can be increased when Selegiline is combined with Tretinoin.
Selpercatinib
The risk or severity of elevated intracranial pressure can be increased when Selpercatinib is combined with Tretinoin.
Serdexmethylphenidate
The risk or severity of elevated intracranial pressure can be increased when Serdexmethylphenidate is combined with Tretinoin.
Sevoflurane
The risk or severity of elevated intracranial pressure can be increased when Sevoflurane is combined with Tretinoin.
Siponimod
The risk or severity of elevated intracranial pressure can be increased when Siponimod is combined with Tretinoin.
Sirolimus
The metabolism of Sirolimus can be decreased when combined with Tretinoin.
Solifenacin
The risk or severity of elevated intracranial pressure can be increased when Solifenacin is combined with Tretinoin.
Solriamfetol
The risk or severity of elevated intracranial pressure can be increased when Solriamfetol is combined with Tretinoin.
Sorafenib
The metabolism of Sorafenib can be decreased when combined with Tretinoin.
Sufentanil
The risk or severity of elevated intracranial pressure can be increased when Sufentanil is combined with Tretinoin.
Sulfasalazine
The risk or severity of elevated intracranial pressure can be increased when Sulfasalazine is combined with Tretinoin.
Sulindac
The risk or severity of elevated intracranial pressure can be increased when Sulindac is combined with Tretinoin.
Sumatriptan
The risk or severity of elevated intracranial pressure can be increased when Sumatriptan is combined with Tretinoin.
Sunitinib
The metabolism of Sunitinib can be decreased when combined with Tretinoin.
Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Tretinoin.
Tamoxifen
The metabolism of Tamoxifen can be decreased when combined with Tretinoin.
Temsirolimus
The metabolism of Temsirolimus can be decreased when combined with Tretinoin.
Teniposide
The metabolism of Teniposide can be decreased when combined with Tretinoin.
Terbutaline
The risk or severity of elevated intracranial pressure can be increased when Terbutaline is combined with Tretinoin.
Tetracycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Tetracycline.
Tetryzoline
The risk or severity of elevated intracranial pressure can be increased when Tetryzoline is combined with Tretinoin.
Thioridazine
The risk or severity of elevated intracranial pressure can be increased when Thioridazine is combined with Tretinoin.
Tigecycline
The risk or severity of pseudotumor cerebri can be increased when Tretinoin is combined with Tigecycline.
Tolmetin
The risk or severity of elevated intracranial pressure can be increased when Tolmetin is combined with Tretinoin.
Tranexamic acid
The risk or severity of hypercoagulability can be increased when Tretinoin is combined with Tranexamic acid.
Tranylcypromine
The risk or severity of elevated intracranial pressure can be increased when Tranylcypromine is combined with Tretinoin.
Trastuzumab emtansine
The metabolism of Trastuzumab emtansine can be decreased when combined with Tretinoin.
Trazodone
The risk or severity of elevated intracranial pressure can be increased when Trazodone is combined with Tretinoin.
Trifluoperazine
The risk or severity of elevated intracranial pressure can be increased when Trifluoperazine is combined with Tretinoin.
Trimipramine
The risk or severity of elevated intracranial pressure can be increased when Trimipramine is combined with Tretinoin.
Valdecoxib
The risk or severity of elevated intracranial pressure can be increased when Valdecoxib is combined with Tretinoin.
Vilanterol
The risk or severity of elevated intracranial pressure can be increased when Vilanterol is combined with Tretinoin.
Vilazodone
The risk or severity of elevated intracranial pressure can be increased when Vilazodone is combined with Tretinoin.
Vincristine
The metabolism of Vincristine can be decreased when combined with Tretinoin.
Vortioxetine
The risk or severity of elevated intracranial pressure can be increased when Vortioxetine is combined with Tretinoin.
Xylometazoline
The risk or severity of elevated intracranial pressure can be increased when Xylometazoline is combined with Tretinoin.
Ziprasidone
The risk or severity of elevated intracranial pressure can be increased when Ziprasidone is combined with Tretinoin.
Zolmitriptan
The risk or severity of elevated intracranial pressure can be increased when Zolmitriptan is combined with Tretinoin.
Abatacept
The metabolism of Tretinoin can be increased when combined with Abatacept.
Adalimumab
The metabolism of Tretinoin can be increased when combined with Adalimumab.
Aminolevulinic acid
The risk or severity of adverse effects can be increased when Tretinoin is combined with Aminolevulinic acid.
Anakinra
The metabolism of Tretinoin can be increased when combined with Anakinra.
Anastrozole
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Anastrozole.
Apalutamide
The serum concentration of Tretinoin can be decreased when it is combined with Apalutamide.
Apremilast
The metabolism of Tretinoin can be increased when combined with Apremilast.
Aprepitant
The metabolism of Tretinoin can be decreased when combined with Aprepitant.
Armodafinil
The metabolism of Tretinoin can be increased when combined with Armodafinil.
Arsenic trioxide
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Arsenic trioxide.
Articaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Articaine.
Avanafil
The serum concentration of Avanafil can be increased when it is combined with Tretinoin.
Beclomethasone dipropionate
The metabolism of Tretinoin can be increased when combined with Beclomethasone dipropionate.
Benzocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Benzocaine.
Benzophenone
The risk or severity of adverse effects can be increased when Tretinoin is combined with Benzophenone.
Benzyl alcohol
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Benzyl alcohol.
Berotralstat
The metabolism of Tretinoin can be decreased when combined with Berotralstat.
Bevacizumab
The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Tretinoin.
Bimekizumab
The metabolism of Tretinoin can be increased when combined with Bimekizumab.
Bleomycin
The risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Tretinoin.
Bortezomib
The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Tretinoin.
Budesonide
The metabolism of Tretinoin can be increased when combined with Budesonide.
Bupivacaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Bupivacaine.
Busulfan
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Busulfan.
Butamben
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Butamben.
Canakinumab
The metabolism of Tretinoin can be increased when combined with Canakinumab.
Capecitabine
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Capecitabine.
Capsaicin
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Capsaicin.
Carmustine
The risk or severity of cardiotoxicity can be increased when Carmustine is combined with Tretinoin.
Cenobamate
The serum concentration of Tretinoin can be decreased when it is combined with Cenobamate.
Certolizumab pegol
The metabolism of Tretinoin can be increased when combined with Certolizumab pegol.
Chloramphenicol
The metabolism of Tretinoin can be decreased when combined with Chloramphenicol.
Chloroprocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Chloroprocaine.
Cimetidine
The metabolism of Tretinoin can be decreased when combined with Cimetidine.
Cinchocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Cinchocaine.
Ciprofloxacin
The metabolism of Tretinoin can be decreased when combined with Ciprofloxacin.
Cisplatin
The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Tretinoin.
Cladribine
The risk or severity of cardiotoxicity can be increased when Cladribine is combined with Tretinoin.
Clobetasol propionate
The metabolism of Tretinoin can be increased when combined with Clobetasol propionate.
Cobicistat
The metabolism of Tretinoin can be decreased when combined with Cobicistat.
Cocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Cocaine.
Cortisone acetate
The metabolism of Tretinoin can be increased when combined with Cortisone acetate.
Cyproheptadine
The risk or severity of adverse effects can be increased when Tretinoin is combined with Cyproheptadine.
Dabrafenib
The risk or severity of adverse effects can be increased when Tretinoin is combined with Dabrafenib.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tretinoin.
Dasatinib
The risk or severity of adverse effects can be increased when Tretinoin is combined with Dasatinib.
Daunorubicin
The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Tretinoin.
Desogestrel
The therapeutic efficacy of Desogestrel can be decreased when used in combination with Tretinoin.
Desvenlafaxine
The metabolism of Tretinoin can be decreased when combined with Desvenlafaxine.
Dexamethasone acetate
The metabolism of Tretinoin can be increased when combined with Dexamethasone acetate.
Dienogest
The therapeutic efficacy of Dienogest can be decreased when used in combination with Tretinoin.
Diphenhydramine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Diphenhydramine.
Doxorubicin
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Doxorubicin.
Drospirenone
The therapeutic efficacy of Drospirenone can be decreased when used in combination with Tretinoin.
Dyclonine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Dyclonine.
Emapalumab
The metabolism of Tretinoin can be increased when combined with Emapalumab.
Encorafenib
The metabolism of Tretinoin can be decreased when combined with Encorafenib.
Enzalutamide
The serum concentration of Tretinoin can be decreased when it is combined with Enzalutamide.
Epcoritamab
The serum concentration of Tretinoin can be increased when it is combined with Epcoritamab.
Epirubicin
The risk or severity of cardiotoxicity can be increased when Epirubicin is combined with Tretinoin.
Erythromycin
The serum concentration of Tretinoin can be increased when it is combined with Erythromycin.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tretinoin.
Esketamine
The risk or severity of hypertension can be increased when Esketamine is combined with Tretinoin.
Estetrol
The therapeutic efficacy of Estetrol can be decreased when used in combination with Tretinoin.
Estradiol
The therapeutic efficacy of Estradiol can be decreased when used in combination with Tretinoin.
Estradiol cypionate
The therapeutic efficacy of Estradiol cypionate can be decreased when used in combination with Tretinoin.
Estradiol valerate
The therapeutic efficacy of Estradiol valerate can be decreased when used in combination with Tretinoin.
Etanercept
The metabolism of Tretinoin can be increased when combined with Etanercept.
Ethinylestradiol
The therapeutic efficacy of Ethinylestradiol can be decreased when used in combination with Tretinoin.
Ethynodiol diacetate
The therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Tretinoin.
Etrasimod
The risk or severity of immunosuppression can be increased when Tretinoin is combined with Etrasimod.
Febuxostat
The risk or severity of adverse effects can be increased when Tretinoin is combined with Febuxostat.
Fedratinib
The serum concentration of Tretinoin can be increased when it is combined with Fedratinib.
Fluconazole
The metabolism of Tretinoin can be decreased when combined with Fluconazole.
Fludarabine
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Fludarabine.
Fluocinonide
The metabolism of Tretinoin can be increased when combined with Fluocinonide.
Fluorouracil
The risk or severity of cardiotoxicity can be increased when Fluorouracil is combined with Tretinoin.
Fluticasone propionate
The metabolism of Tretinoin can be decreased when combined with Fluticasone propionate.
Fluvoxamine
The metabolism of Tretinoin can be decreased when combined with Fluvoxamine.
Fosdenopterin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Fosdenopterin.
Fosnetupitant
The metabolism of Tretinoin can be decreased when combined with Fosnetupitant.
Fusidic acid
The metabolism of Tretinoin can be decreased when combined with Fusidic acid.
Gestodene
The therapeutic efficacy of Gestodene can be decreased when used in combination with Tretinoin.
Glofitamab
The serum concentration of Tretinoin can be increased when it is combined with Glofitamab.
Golimumab
The metabolism of Tretinoin can be increased when combined with Golimumab.
Haloperidol
The serum concentration of Haloperidol can be increased when it is combined with Tretinoin.
Hexaminolevulinate
The risk or severity of adverse effects can be increased when Tretinoin is combined with Hexaminolevulinate.
Hydroxyprogesterone caproate
The therapeutic efficacy of Hydroxyprogesterone caproate can be decreased when used in combination with Tretinoin.
Idarubicin
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Idarubicin.
Imatinib
The risk or severity of cardiotoxicity can be increased when Imatinib is combined with Tretinoin.
Infliximab
The metabolism of Tretinoin can be increased when combined with Infliximab.
Isavuconazonium
The metabolism of Tretinoin can be decreased when combined with Isavuconazonium.
Isoniazid
The metabolism of Tretinoin can be decreased when combined with Isoniazid.
Isradipine
The metabolism of Tretinoin can be decreased when combined with Isradipine.
Itraconazole
The risk or severity of adverse effects can be increased when Tretinoin is combined with Itraconazole.
Ivacaftor
The serum concentration of Tretinoin can be increased when it is combined with Ivacaftor.
Ivosidenib
The metabolism of Tretinoin can be increased when combined with Ivosidenib.
Lamotrigine
The risk or severity of adverse effects can be increased when Tretinoin is combined with Lamotrigine.
Letermovir
The metabolism of Tretinoin can be decreased when combined with Letermovir.
Levofloxacin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Levofloxacin.
Levonorgestrel
The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Tretinoin.
Lidocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Lidocaine.
Linagliptin
The metabolism of Tretinoin can be decreased when combined with Linagliptin.
Losartan
The risk or severity of adverse effects can be increased when Tretinoin is combined with Losartan.
Mavacamten
The serum concentration of Tretinoin can be decreased when it is combined with Mavacamten.
Mechlorethamine
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Mechlorethamine.
Medroxyprogesterone acetate
The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Tretinoin.
Megestrol acetate
The therapeutic efficacy of Megestrol acetate can be decreased when used in combination with Tretinoin.
Mepivacaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Mepivacaine.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Tretinoin.
Methoxsalen
The risk or severity of adverse effects can be increased when Tretinoin is combined with Methoxsalen.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tretinoin.
Methyl aminolevulinate
The risk or severity of adverse effects can be increased when Tretinoin is combined with Methyl aminolevulinate.
Metoprolol
The risk or severity of adverse effects can be increased when Tretinoin is combined with Metoprolol.
Miconazole
The metabolism of Tretinoin can be decreased when combined with Miconazole.
Mifepristone
The metabolism of Tretinoin can be decreased when combined with Mifepristone.
Milnacipran
The metabolism of Tretinoin can be decreased when combined with Milnacipran.
Mitomycin
The risk or severity of cardiotoxicity can be increased when Mitomycin is combined with Tretinoin.
Mitoxantrone
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Mitoxantrone.
Modafinil
The metabolism of Tretinoin can be increased when combined with Modafinil.
Mometasone furoate
The metabolism of Tretinoin can be increased when combined with Mometasone furoate.
Netupitant
The metabolism of Tretinoin can be decreased when combined with Netupitant.
Nicardipine
The metabolism of Tretinoin can be decreased when combined with Nicardipine.
Nilotinib
The risk or severity of adverse effects can be increased when Tretinoin is combined with Nilotinib.
Norethisterone
The therapeutic efficacy of Norethisterone can be decreased when used in combination with Tretinoin.
Norgestimate
The therapeutic efficacy of Norgestimate can be decreased when used in combination with Tretinoin.
Norgestrel
The therapeutic efficacy of Norgestrel can be decreased when used in combination with Tretinoin.
Orlistat
Orlistat can cause a decrease in the absorption of Tretinoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxcarbazepine
The risk or severity of adverse effects can be increased when Tretinoin is combined with Oxcarbazepine.
Oxybuprocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Oxybuprocaine.
Peginterferon alfa-2a
The risk or severity of cardiotoxicity can be increased when Peginterferon alfa-2a is combined with Tretinoin.
Pentostatin
The risk or severity of cardiotoxicity can be increased when Pentostatin is combined with Tretinoin.
Pertuzumab
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Pertuzumab.
Phenol
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Phenol.
Pitolisant
The serum concentration of Tretinoin can be decreased when it is combined with Pitolisant.
Porfimer sodium
The risk or severity of adverse effects can be increased when Tretinoin is combined with Porfimer sodium.
Pralsetinib
The metabolism of Tretinoin can be decreased when combined with Pralsetinib.
Pramocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Pramocaine.
Prasterone
The metabolism of Tretinoin can be decreased when combined with Prasterone.
Prednisolone phosphate
The metabolism of Tretinoin can be increased when combined with Prednisolone phosphate.
Prilocaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Prilocaine.
Primaquine
The metabolism of Tretinoin can be decreased when combined with Primaquine.
Procaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Procaine.
Progesterone
The metabolism of Tretinoin can be decreased when combined with Progesterone.
Proparacaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Proparacaine.
Repotrectinib
The metabolism of Tretinoin can be decreased when combined with Repotrectinib.
Reserpine
The metabolism of Tretinoin can be increased when combined with Reserpine.
Riboflavin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Riboflavin.
Rilonacept
The metabolism of Tretinoin can be increased when combined with Rilonacept.
Ritlecitinib
The serum concentration of Tretinoin can be increased when it is combined with Ritlecitinib.
Ritonavir
The serum concentration of Tretinoin can be increased when it is combined with Ritonavir.
Ropivacaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Ropivacaine.
Rucaparib
The metabolism of Tretinoin can be decreased when combined with Rucaparib.
Satralizumab
The serum concentration of Tretinoin can be decreased when it is combined with Satralizumab.
Secukinumab
The metabolism of Tretinoin can be increased when combined with Secukinumab.
Siltuximab
The metabolism of Tretinoin can be increased when combined with Siltuximab.
Sotorasib
The serum concentration of Tretinoin can be decreased when it is combined with Sotorasib.
Stiripentol
The metabolism of Tretinoin can be decreased when combined with Stiripentol.
Telotristat ethyl
The serum concentration of Tretinoin can be decreased when it is combined with Telotristat ethyl.
Testosterone undecanoate
Testosterone undecanoate may increase the hypertensive activities of Tretinoin.
Tetracaine
The risk or severity of methemoglobinemia can be increased when Tretinoin is combined with Tetracaine.
Thalidomide
The risk or severity of cardiotoxicity can be increased when Tretinoin is combined with Thalidomide.
Titanium dioxide
The risk or severity of adverse effects can be increased when Tretinoin is combined with Titanium dioxide.
Tocilizumab
The metabolism of Tretinoin can be increased when combined with Tocilizumab.
Trastuzumab
The risk or severity of cardiotoxicity can be increased when Trastuzumab is combined with Tretinoin.
Triamcinolone
The metabolism of Tretinoin can be increased when combined with Triamcinolone.
Tucatinib
The metabolism of Tucatinib can be decreased when combined with Tretinoin.
Valproic acid
Valproic acid may increase the Pseudotumor Cerebri activities of Tretinoin.
Vemurafenib
The risk or severity of adverse effects can be increased when Tretinoin is combined with Vemurafenib.
Venetoclax
The metabolism of Tretinoin can be decreased when combined with Venetoclax.
Verapamil
The metabolism of Tretinoin can be decreased when combined with Verapamil.
Verteporfin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Verteporfin.
Vinblastine
The risk or severity of cardiotoxicity can be increased when Vinblastine is combined with Tretinoin.
Vinorelbine
The risk or severity of cardiotoxicity can be increased when Vinorelbine is combined with Tretinoin.
Vitamin A
The risk or severity of adverse effects can be increased when Vitamin A is combined with Tretinoin.
Acalabrutinib
The metabolism of Tretinoin can be decreased when combined with Acalabrutinib.
Acebutolol
Tretinoin may decrease the antihypertensive activities of Acebutolol.
Aliskiren
Tretinoin may decrease the antihypertensive activities of Aliskiren.
Alprazolam
The metabolism of Tretinoin can be decreased when combined with Alprazolam.
Ambrisentan
Tretinoin may decrease the antihypertensive activities of Ambrisentan.
Amiodarone
The metabolism of Tretinoin can be decreased when combined with Amiodarone.
Amlodipine
Tretinoin may decrease the antihypertensive activities of Amlodipine.
Apixaban
The metabolism of Apixaban can be decreased when combined with Tretinoin.
Apomorphine
The metabolism of Tretinoin can be decreased when combined with Apomorphine.
Aprocitentan
Tretinoin may decrease the antihypertensive activities of Aprocitentan.
Artemether
The metabolism of Artemether can be decreased when combined with Tretinoin.
Asunaprevir
The metabolism of Asunaprevir can be decreased when combined with Tretinoin.
Atazanavir
The metabolism of Tretinoin can be decreased when combined with Atazanavir.
Atenolol
Tretinoin may decrease the antihypertensive activities of Atenolol.
Atorvastatin
The metabolism of Atorvastatin can be decreased when combined with Tretinoin.
Azelastine
The metabolism of Azelastine can be decreased when combined with Tretinoin.
Azilsartan medoxomil
Tretinoin may decrease the antihypertensive activities of Azilsartan medoxomil.
Benazepril
Tretinoin may decrease the antihypertensive activities of Benazepril.
Bendroflumethiazide
Tretinoin may decrease the antihypertensive activities of Bendroflumethiazide.
Betamethasone
The metabolism of Tretinoin can be increased when combined with Betamethasone.
Betaxolol
Tretinoin may decrease the antihypertensive activities of Betaxolol.
Bisoprolol
Tretinoin may decrease the antihypertensive activities of Bisoprolol.
Bosentan
Tretinoin may decrease the antihypertensive activities of Bosentan.
Bretylium
Tretinoin may decrease the antihypertensive activities of Bretylium.
Buprenorphine
The metabolism of Buprenorphine can be decreased when combined with Tretinoin.
Candesartan cilexetil
Tretinoin may decrease the antihypertensive activities of Candesartan cilexetil.
Captopril
Tretinoin may decrease the antihypertensive activities of Captopril.
Carbamazepine
The metabolism of Tretinoin can be increased when combined with Carbamazepine.
Carvedilol
Tretinoin may decrease the antihypertensive activities of Carvedilol.
Chloroquine
The metabolism of Tretinoin can be decreased when combined with Chloroquine.
Chlorothiazide
Tretinoin may decrease the antihypertensive activities of Chlorothiazide.
Chlorpheniramine
The metabolism of Chlorpheniramine can be decreased when combined with Tretinoin.
Chlorthalidone
Tretinoin may decrease the antihypertensive activities of Chlorthalidone.
Cilostazol
The metabolism of Cilostazol can be decreased when combined with Tretinoin.
Clarithromycin
The metabolism of Tretinoin can be decreased when combined with Clarithromycin.
Clindamycin
The metabolism of Clindamycin can be decreased when combined with Tretinoin.
Clopidogrel
The metabolism of Clopidogrel can be decreased when combined with Tretinoin.
Conivaptan
The metabolism of Tretinoin can be decreased when combined with Conivaptan.
Curcumin
The metabolism of Tretinoin can be decreased when combined with Curcumin.
Danazol
The metabolism of Tretinoin can be decreased when combined with Danazol.
Dapsone
The metabolism of Tretinoin can be decreased when combined with Dapsone.
Dapsone
The risk or severity of adverse effects can be increased when Benzoyl peroxide is combined with Dapsone.
Darunavir
The metabolism of Tretinoin can be decreased when combined with Darunavir.
Dasiglucagon
Tretinoin may decrease the antihypertensive activities of Dasiglucagon.
Deutetrabenazine
The metabolism of Deutetrabenazine can be decreased when combined with Tretinoin.
Dexamethasone
The metabolism of Tretinoin can be increased when combined with Dexamethasone.
Dextromethorphan
The metabolism of Tretinoin can be decreased when combined with Dextromethorphan.
Diazepam
The metabolism of Diazepam can be decreased when combined with Tretinoin.
Diazoxide
Tretinoin may decrease the antihypertensive activities of Diazoxide.
Digoxin
Digoxin may decrease the cardiotoxic activities of Tretinoin.
Disulfiram
The metabolism of Disulfiram can be decreased when combined with Tretinoin.
Doravirine
The metabolism of Doravirine can be decreased when combined with Tretinoin.
Doxazosin
Tretinoin may decrease the antihypertensive activities of Doxazosin.
Econazole
The metabolism of Tretinoin can be decreased when combined with Econazole.
Efavirenz
The metabolism of Tretinoin can be decreased when combined with Efavirenz.
Elbasvir
The metabolism of Elbasvir can be decreased when combined with Tretinoin.
Elexacaftor
The metabolism of Elexacaftor can be decreased when combined with Tretinoin.
Elvitegravir
The metabolism of Tretinoin can be decreased when combined with Elvitegravir.
Enalapril
Tretinoin may decrease the antihypertensive activities of Enalapril.
Enalaprilat
Tretinoin may decrease the antihypertensive activities of Enalaprilat.
Eplerenone
Tretinoin may decrease the antihypertensive activities of Eplerenone.
Epoprostenol
Tretinoin may decrease the antihypertensive activities of Epoprostenol.
Eprosartan
Tretinoin may decrease the antihypertensive activities of Eprosartan.
Esmolol
Tretinoin may decrease the antihypertensive activities of Esmolol.
Estradiol acetate
The metabolism of Estradiol acetate can be decreased when combined with Tretinoin.
Felodipine
Tretinoin may decrease the antihypertensive activities of Felodipine.
Fenoldopam
Tretinoin may decrease the antihypertensive activities of Fenoldopam.
Fexinidazole
The metabolism of Fexinidazole can be decreased when combined with Tretinoin.
Flutamide
The metabolism of Tretinoin can be decreased when combined with Flutamide.
Fluticasone furoate
The metabolism of Fluticasone furoate can be decreased when combined with Tretinoin.
Fluvastatin
The metabolism of Fluvastatin can be decreased when combined with Tretinoin.
Fosinopril
Tretinoin may decrease the antihypertensive activities of Fosinopril.
Fosphenytoin
The metabolism of Tretinoin can be increased when combined with Fosphenytoin.
Fruquintinib
The metabolism of Fruquintinib can be decreased when combined with Tretinoin.
Furosemide
Tretinoin may decrease the antihypertensive activities of Furosemide.
Gefitinib
The metabolism of Tretinoin can be decreased when combined with Gefitinib.
Glyburide
The metabolism of Glyburide can be decreased when combined with Tretinoin.
Hydralazine
Tretinoin may decrease the antihypertensive activities of Hydralazine.
Hydrochlorothiazide
Tretinoin may decrease the antihypertensive activities of Hydrochlorothiazide.
Hydrocortisone
The metabolism of Tretinoin can be decreased when combined with Hydrocortisone.
Hydrocortisone acetate
The metabolism of Hydrocortisone acetate can be decreased when combined with Tretinoin.
Hydrocortisone butyrate
The metabolism of Hydrocortisone butyrate can be decreased when combined with Tretinoin.
Hydroflumethiazide
Tretinoin may decrease the antihypertensive activities of Hydroflumethiazide.
Hydroxyzine
The metabolism of Tretinoin can be decreased when combined with Hydroxyzine.
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Tretinoin.
Indapamide
Tretinoin may decrease the antihypertensive activities of Indapamide.
Indinavir
The metabolism of Tretinoin can be decreased when combined with Indinavir.
Irbesartan
Tretinoin may decrease the antihypertensive activities of Irbesartan.
Irinotecan
The metabolism of Irinotecan can be decreased when combined with Tretinoin.
Istradefylline
The metabolism of Istradefylline can be decreased when combined with Tretinoin.
Ketoconazole
The metabolism of Tretinoin can be decreased when combined with Ketoconazole.
Labetalol
Tretinoin may decrease the antihypertensive activities of Labetalol.
Landiolol
Tretinoin may decrease the antihypertensive activities of Landiolol.
Lapatinib
The metabolism of Lapatinib can be decreased when combined with Tretinoin.
Lemborexant
The metabolism of Lemborexant can be decreased when combined with Tretinoin.
Levamlodipine
Tretinoin may decrease the antihypertensive activities of Levamlodipine.
Levoketoconazole
The metabolism of Tretinoin can be decreased when combined with Levoketoconazole.
Lisinopril
Tretinoin may decrease the antihypertensive activities of Lisinopril.
Lonafarnib
The metabolism of Tretinoin can be decreased when combined with Lonafarnib.
Lopinavir
The metabolism of Tretinoin can be decreased when combined with Lopinavir.
Lorlatinib
The metabolism of Lorlatinib can be decreased when combined with Tretinoin.
Lovastatin
The metabolism of Tretinoin can be decreased when combined with Lovastatin.
Lumacaftor
The metabolism of Tretinoin can be increased when combined with Lumacaftor.
Macitentan
Tretinoin may decrease the antihypertensive activities of Macitentan.
Mecamylamine
Tretinoin may decrease the antihypertensive activities of Mecamylamine.
Methimazole
The metabolism of Tretinoin can be decreased when combined with Methimazole.
Methyldopa
Tretinoin may decrease the antihypertensive activities of Methyldopa.
Metolazone
Tretinoin may decrease the antihypertensive activities of Metolazone.
Metreleptin
The metabolism of Tretinoin can be increased when combined with Metreleptin.
Metronidazole
The metabolism of Metronidazole can be decreased when combined with Tretinoin.
Metyrosine
Tretinoin may decrease the antihypertensive activities of Metyrosine.
Midazolam
The metabolism of Tretinoin can be decreased when combined with Midazolam.
Midostaurin
The metabolism of Tretinoin can be decreased when combined with Midostaurin.
Minoxidil
Tretinoin may decrease the antihypertensive activities of Minoxidil.
Mitotane
The metabolism of Tretinoin can be increased when combined with Mitotane.
Moexipril
Tretinoin may decrease the antihypertensive activities of Moexipril.
Mycophenolate mofetil
The metabolism of Tretinoin can be decreased when combined with Mycophenolate mofetil.
Nadolol
Tretinoin may decrease the antihypertensive activities of Nadolol.
Nateglinide
The metabolism of Tretinoin can be decreased when combined with Nateglinide.
Nebivolol
Tretinoin may decrease the antihypertensive activities of Nebivolol.
Nelfinavir
The metabolism of Tretinoin can be decreased when combined with Nelfinavir.
Nevirapine
The metabolism of Tretinoin can be decreased when combined with Nevirapine.
Nifedipine
The metabolism of Nifedipine can be decreased when combined with Tretinoin.
Nimodipine
Tretinoin may decrease the antihypertensive activities of Nimodipine.
Nisoldipine
Tretinoin may decrease the antihypertensive activities of Nisoldipine.
Nitroglycerin
Tretinoin may decrease the antihypertensive activities of Nitroglycerin.
Nitroprusside
Tretinoin may decrease the antihypertensive activities of Nitroprusside.
Olmesartan
Tretinoin may decrease the antihypertensive activities of Olmesartan.
Omaveloxolone
The serum concentration of Tretinoin can be decreased when it is combined with Omaveloxolone.
Ondansetron
The metabolism of Ondansetron can be decreased when combined with Tretinoin.
Osilodrostat
The metabolism of Tretinoin can be decreased when combined with Osilodrostat.
Oxybutynin
The metabolism of Oxybutynin can be decreased when combined with Tretinoin.
Oxycodone
The metabolism of Tretinoin can be decreased when combined with Oxycodone.
Paritaprevir
The metabolism of Paritaprevir can be decreased when combined with Tretinoin.
Pentamidine
The metabolism of Tretinoin can be decreased when combined with Pentamidine.
Pentobarbital
The metabolism of Tretinoin can be increased when combined with Pentobarbital.
Perampanel
The metabolism of Perampanel can be decreased when combined with Tretinoin.
Perindopril
Tretinoin may decrease the antihypertensive activities of Perindopril.
Phenobarbital
The metabolism of Tretinoin can be increased when combined with Phenobarbital.
Phenytoin
The metabolism of Tretinoin can be increased when combined with Phenytoin.
Pindolol
Tretinoin may decrease the antihypertensive activities of Pindolol.
Polythiazide
Tretinoin may decrease the antihypertensive activities of Polythiazide.
Ponesimod
The metabolism of Ponesimod can be decreased when combined with Tretinoin.
Posaconazole
The metabolism of Tretinoin can be decreased when combined with Posaconazole.
Praziquantel
The metabolism of Praziquantel can be decreased when combined with Tretinoin.
Prazosin
Tretinoin may decrease the antihypertensive activities of Prazosin.
Primidone
The metabolism of Tretinoin can be increased when combined with Primidone.
Propranolol
Tretinoin may decrease the antihypertensive activities of Propranolol.
Quinapril
Tretinoin may decrease the antihypertensive activities of Quinapril.
Quinine
The metabolism of Tretinoin can be decreased when combined with Quinine.
Quizartinib
The metabolism of Quizartinib can be decreased when combined with Tretinoin.
Ramipril
Tretinoin may decrease the antihypertensive activities of Ramipril.
Relugolix
The metabolism of Relugolix can be decreased when combined with Tretinoin.
Ribociclib
The metabolism of Tretinoin can be decreased when combined with Ribociclib.
Rifampin
The metabolism of Tretinoin can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Tretinoin can be increased when combined with Rifapentine.
Riociguat
Tretinoin may decrease the antihypertensive activities of Riociguat.
Rivaroxaban
The metabolism of Rivaroxaban can be decreased when combined with Tretinoin.
Romidepsin
The metabolism of Romidepsin can be decreased when combined with Tretinoin.
Saquinavir
The metabolism of Tretinoin can be decreased when combined with Saquinavir.
Saxagliptin
The metabolism of Saxagliptin can be decreased when combined with Tretinoin.
Selexipag
Tretinoin may decrease the antihypertensive activities of Selexipag.
Selumetinib
The metabolism of Selumetinib can be decreased when combined with Tretinoin.
Sildenafil
The metabolism of Tretinoin can be decreased when combined with Sildenafil.
Simvastatin
The metabolism of Tretinoin can be decreased when combined with Simvastatin.
Somatrogon
The metabolism of Tretinoin can be increased when combined with Somatrogon.
Sotatercept
Tretinoin may decrease the antihypertensive activities of Sotatercept.
Spironolactone
Tretinoin may decrease the antihypertensive activities of Spironolactone.
Tadalafil
Tretinoin may decrease the antihypertensive activities of Tadalafil.
Telithromycin
The metabolism of Tretinoin can be decreased when combined with Telithromycin.
Telmisartan
Tretinoin may decrease the antihypertensive activities of Telmisartan.
Terazosin
Tretinoin may decrease the antihypertensive activities of Terazosin.
Testosterone
The metabolism of Tretinoin can be decreased when combined with Testosterone.
Testosterone cypionate
The metabolism of Testosterone cypionate can be decreased when combined with Tretinoin.
Testosterone enanthate
The metabolism of Testosterone enanthate can be decreased when combined with Tretinoin.
Tezacaftor
The metabolism of Tezacaftor can be decreased when combined with Tretinoin.
Ticagrelor
The metabolism of Ticagrelor can be decreased when combined with Tretinoin.
Timolol
Tretinoin may decrease the antihypertensive activities of Timolol.
Tipranavir
The metabolism of Tretinoin can be decreased when combined with Tipranavir.
Tocopherylquinone
Tretinoin may decrease the antihypertensive activities of Tocopherylquinone.
Torasemide
Tretinoin may decrease the antihypertensive activities of Torasemide.
Trandolapril
Tretinoin may decrease the antihypertensive activities of Trandolapril.
Treprostinil
Tretinoin may decrease the antihypertensive activities of Treprostinil.
Triazolam
The metabolism of Triazolam can be decreased when combined with Tretinoin.
Vadadustat
The serum concentration of Tretinoin can be increased when it is combined with Vadadustat.
Valbenazine
The metabolism of Valbenazine can be decreased when combined with Tretinoin.
Valsartan
Tretinoin may decrease the antihypertensive activities of Valsartan.
Vardenafil
The metabolism of Vardenafil can be decreased when combined with Tretinoin.
Viloxazine
The metabolism of Tretinoin can be decreased when combined with Viloxazine.
Vonoprazan
The metabolism of Vonoprazan can be decreased when combined with Tretinoin.
Voriconazole
The metabolism of Tretinoin can be decreased when combined with Voriconazole.
Zaleplon
The metabolism of Zaleplon can be decreased when combined with Tretinoin.
Zonisamide
The metabolism of Zonisamide can be decreased when combined with Tretinoin.